Rivaroxaban CAS 366789-02-8 Purity >99.5% (HPLC) Factory API Kounga Teitei
Kaihanga Kaihanga Rivaroxaban Kaiwaenga e Pa ana:
(S)-(+)-Glycidyl Phthalimide CAS 161596-47-0
4-(4-Aminophenyl)morpholin-3-one CAS 438056-69-0
Rivaroxaban Intermediate CAS 446292-07-5
5-Chlorothiophene-2-Waharawakawa CAS 24065-33-6
5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9
Rivaroxaban API CAS 366789-02-8
Ingoa matū | Rivaroxaban |
Nga kupu taurite | (S)-Rivaroxaban;(S)-5-Chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)-oxazolidin-5-yl)methyl)thiophene-2-carbox;BAY 59-7939 |
Tau CAS | 366789-02-8 |
Tūnga Taonga | I roto i te Stock, Production Tauine Up ki Taranata |
Tātai rāpoi | C19H18ClN3O5S |
Taumaha rāpoi | 435.88 |
Waitohu | Ruifu Chemical |
Tūemi | Whakatakotoranga |
Te ahua | Paura ma, tata ma ranei |
Tautuhi A | Ko te whakaurunga infrared o Rivaroxaban e rite ana ki nga paerewa tohutoro |
Tautuhinga B | Ko te wa pupuri o te tihi matua o te otinga tauira e rite ana ki tera o te otinga pai o te punaha, i riro mai i te purea enantiomeric. |
Enantiomeric Pure | RVX RC01: ≤0.15% |
makuku (KF) | ≤0.50% |
Te pungarehu whanariki | ≤0.10% |
Nga Korewa Taamaha | ≤20ppm |
Waikawa Acetic | ≤5000ppm |
Matū Paatahi (HPLC) | |
RVX RC02 | ≤0.15% |
RVX RC03 | ≤0.15% |
RVX RC04 | ≤0.15% |
RVX RC05 | ≤0.15% |
RVX RC06 | ≤0.15% |
RVX RC07 | ≤0.15% |
RVX RC08 | ≤0.15% |
Tetahi atu poke takitahi | ≤0.10% |
Nga poke katoa | <0.50% |
Wairewa Toenga (GC) | |
Ewaro | ≤5000ppm |
Toluene | ≤890ppm |
Triethylamine | ≤320ppm |
Te Maama / Tikanga Tatauria | >99.5% (HPLC) (i runga i te waikore) |
Paerewa Whakamatau | Paerewa hinonga |
Whakamahinga | API;Ta'auau Antithrombotic;FXa Inhibitor |
Mōkī: Pounamu, Peeke konumohe konumohe, 25kg / Cardboard Drum, kia rite ranei ki te hiahia a te kaihoko.
Tikanga Rokiroki:Whakaorangia i roto i nga ipu kua hiri ki te waahi makariri me te maroke;Tiaki i te marama me te makuku.
Rivaroxaban(CAS:366789-02-8) (Xarelto, Bayer) he anticoagulant waha.He aukati tika Xa a-waha.Ko te Rivaroxaban e tohuhia ana mo te 'maimoatanga o te thrombosis vein hohonu me te embolism pulmonary, me te aukati i te thrombosis uaua hohonu me te embolism pulmonary i roto i nga pakeke'.Mo te maimoatanga tuatahi o te pulmonary embolism whakapeka, ko te horopeta o te rivaroxaban he 15 mg e rua nga ra ia ra mo nga ra tuatahi 21 ka whai i te 20 mg kotahi ia ra mo te maimoatanga tonu me te aukati i te thromboembolism venous recurrent.Non-Valvular Atrial Fibrillation (NVAF) ki te aukati i te whiu me te embolism pūnaha.Te maimoatanga VTE whakapeka me te aukati i te VTE auau [mo te thrombosis uaua hohonu (DVT) me te pulmonary embolism (PE)].Te aukati i nga kaupapa thromboembolic venous (VTE) i roto i te kowhiringa katoa o te hip, te pokanga whakakapi turi ranei (THR, TKR).